Advertisement

Long term treatment of SDAT patients with pyritinol

  • S. Knezevic
  • Z. Mubrin
  • G. Spilich
  • G. Vucinic
  • W. Wannenmacher
Part of the Key Topics in Brain Research book series (KEYTOPICS)

Summary

A group of 26 patients with the clinical diagnosis of Senile Dementia of Alzheimer’s type (SDAT) was randomly assigned in a double blind cross-over trial of pyritinol versus placebo. Psychiatric and neurological examination, psychometric testing and regional cerebral blood flow measurements were used to assess the effects of medication. Pyritinol had a beneficial effect on cognitive performance which was sustained during the long term follow up of one year.

Keywords

Word Pair Regional Cerebral Blood Flow Target Sentence Demented Patient Soft Neurological Sign 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Cohen G (1979) Language and comprehension in old age. Cognitive Psychology 11: 412–429PubMedCrossRefGoogle Scholar
  2. Cohen G, Faulkner D (1981) Memory for discourse in old age. Discourse Processes 4: 253–265CrossRefGoogle Scholar
  3. Cooper AJ, Magnus RV (1980) A placebo-controlled study of pyritinol ( Encephabol) in dementia. Pharmatherapeutica 2: 317–323PubMedGoogle Scholar
  4. Erzigkeit H (1986) Der Syndrom-Kurztest zur Erfassung von Aufmerksamkeitsund Gedächtnisstörungen. Vless, VaterstettenGoogle Scholar
  5. Greiner HE, Haase AF, Seyfried CA (1988) Biochemical models for the study of the mechanism of action of an encephalotropic drug. In: Kanowski S, Ladurner G (eds) Dementielle Erkrankungen im Alter. Pathogenetische Modelle und Therapeutische Wirklichkeit. Thieme, Stuttgart, S 45–51Google Scholar
  6. Hamouz W (1977) The use of pyritinol in patients with moderate to severe organic psychosyndrome. Pharmatherapeutica 1: 398–403Google Scholar
  7. Herrmann WM, Kern U, Rohmel J (1986) The effects of pyritinol on functional deficits of patients with organic mental disorders. Pharmacopsychiatry 19: 378–385PubMedCrossRefGoogle Scholar
  8. Hoyer S, Oesterreich K, Stoll KD (1977) Effects of pyritinol-HC1 on blood flow and oxidative metabolism of the brain in patients with dementia. Drug Res 27: 671–674Google Scholar
  9. Knezevic S, Mubrin Z, Risberg J, Vucinic G, Spilich G, Gubarev N, Wannenmacher W (1989) Pyritinol treatment of SDAT patients: evaluation by psychiatric and neurological examination, psychometric testing and rCBF measurements. Clin Psychopharmacol 4: 25–38CrossRefGoogle Scholar
  10. Martin KJ, Vyas S (1987) Increase in acetylcholine concentration in the brain of “old” rats following treatment with pyrithioxine ( Encephabol ). Br J Pharmacol 90: 561–569Google Scholar
  11. Maximilian VA, Brawanski A (1988) Functional and vascular challenge procedures during noninvasive rCBF measurements. In: Knezevic S, Maximilian VA, Mubrin V, Prohovnik I, Wade J (eds) Handbook of regional cerebral blood flow. Lawrence Erlbaum Associates, Hove and London, pp 79–121Google Scholar
  12. Mubrin Z, Knezevic S, Barac B, Poljakovic Z, Pudar-Klein M, Katic Z (1985a) Effect of mental activation on regional cerebral blood flow (rCBF) changes in patients with cerebrovascular disease. Neurologija (Zagreb) 31: 107–124Google Scholar
  13. Mubrin Z, Knezevic S, Barac B, Gubarev N, Lazic M, Liscic R, Vidosic S (1985b) Distinct rCBF pattern during different types of short-term memory activation. In: Hartmann A, Hoyer S (eds) Cerebral blood flow and metabolism measurement. Springer, Berlin Heidelberg New York Tokyo, pp 81–87CrossRefGoogle Scholar
  14. Obrist WD, Thompson HK, Wang HS, Wilkinson WE (1975) Regional cerebral blood flow estimated by 133Xenon inhalation. Stroke 6: 245–256PubMedCrossRefGoogle Scholar
  15. Oswald WD, Oswald B, Grobe D, Lukaschek K, Sappa J, Fleischmann UM (1986) Recent approaches in the treatment and assessment of psychoorganic brain-syndromes. A double-blind study with pyritinol. In: Ramos GG, Herrmann WM, Otero E, Toledano A (eds) Advances in the field of cerebrovascular disease. Egrat, Madrid, pp 88–96Google Scholar
  16. Pavlik A, Benesova O, Dlohozkova N (1987) Effects of nootropic drugs on brain cholinergic and dopaminergic transmission. Act Nery Sup 29: 62–65Google Scholar
  17. Risberg J (1980) Regional cerebral blood flow measurements by 133Xe-inhalation: methodology and applications in neuropsychology and psychiatry. Brain Lang 9: 9–34PubMedCrossRefGoogle Scholar
  18. Risberg J (1985) Application of the nontraumatic xenon 133 method in neuropsychiatry. In: Hartmann A, Hoyer S (eds) Cerebral blood flow and metabolism measurement. Springer, Berlin Heidelberg New York Tokyo, pp 72–80CrossRefGoogle Scholar
  19. Risberg J, Ali Z, Wilson EM, Wills EL, Halsey JH Jr (1975) Regional cerebral blood flow by 133Xenon inhalation. Preliminary evaluation of an initial slope index in patients with unstable flow compartments. Stroke 6: 142–148Google Scholar
  20. Rosen WG, Mohs RC, Davis KL (1984) A new rating scale for Alzheimer’s disease. Am J Psychiatry 141: 1356–1365PubMedGoogle Scholar
  21. Rosen WG, Terry RD, Fuld PA, et al (1980) Pathological verification of ischemic score in differentiation of demential. Ann Neurol 7: 486–488PubMedCrossRefGoogle Scholar
  22. Spilich GJ (1983) Life-span components of text processing: structural and procedural differences. Journal of Verbal Learning and Verbal Behavior 22: 231–244CrossRefGoogle Scholar
  23. Spilich GJ (1985) Discourse comprehension across the span of life. In: Charness N (ed) Aging and human performance. Wiley, New York, pp 143–190Google Scholar
  24. Spilich GJ, Voss JF (1983) Contextual effects upon text memory for young, aged-normal, and aged memory-impaired individuals. Exp Aging Res 9: 45–49PubMedGoogle Scholar
  25. Venn RD (1983) The Sandoz clinical assessment geriatric (SCAG) scale. Gerontology 29: 185–198PubMedCrossRefGoogle Scholar
  26. Wechsler D (1945) A standardized memory scale for clinical use. J Psychol 27: 91–94Google Scholar

Copyright information

© Springer-Verlag Wien 1990

Authors and Affiliations

  • S. Knezevic
    • 1
  • Z. Mubrin
    • 2
  • G. Spilich
    • 3
  • G. Vucinic
    • 4
  • W. Wannenmacher
    • 5
  1. 1.Department of NeurologyUniversity of Zagreb Medical SchoolYugoslavia
  2. 2.Memory Center of the University Hospital CentreZagrebYugoslavia
  3. 3.Washington CollegeChestertownUSA
  4. 4.Department of PsychiatryUniversity Hospital CentreZagrebYugoslavia
  5. 5.Institute of PsychologyUniversity of TechnologyDarmstadtFederal Republic of Germany

Personalised recommendations